Ansell Ltd (ASX: ANN) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Ansell Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Ansell Ltd (ASX: ANN)
Latest News
Share Market News
Here are the top 10 ASX 200 shares today
Share Fallers
Why Ansell, Aurizon, Metcash, and Syrah shares are sinking today
Industrials Shares
Why is the Ansell share price crashing 13% today?
Share Fallers
8 ASX shares that were COVID winners but have now crashed
Broker Notes
How this fundie plans to keep investing through a recession
How to invest
My $10-a-day approach to building a second income with ASX shares
Broker Notes
Morgans warns that these ASX shares could disappoint in FY23
Share Market News
6 ASX 200 directors buying up their company shares in the past week
Opinions
I’d invest $5,000 into these excellent ASX shares for the long term
Dividend Investing
8 ASX 200 shares trading ex-dividend this week
Share Fallers
Why Ansell, Breville, Star, and Temple & Webster shares are falling
Earnings Results
Ansell share price slumps 8% as healthcare sales fail to cough up
Frequently Asked Questions
-
Yes, Ansell has historically paid two unfranked or partially franked dividends per year.
-
Ansell pays its shareholder dividends in March and September.
-
Ansell Ltd listed on the ASX on 22 August 1985.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
20 Feb 2023 | $0.2915 | 0.00% | Interim | 09 Mar 2023 |
29 Aug 2022 | $0.4518 | 0.00% | Final | 15 Sep 2022 |
21 Feb 2022 | $0.3367 | 0.00% | Interim | 09 Mar 2022 |
30 Aug 2021 | $0.5944 | 0.00% | Final | 16 Sep 2021 |
22 Feb 2021 | $0.4190 | 0.00% | Interim | 10 Mar 2021 |
31 Aug 2020 | $0.3811 | 0.00% | Final | 17 Sep 2020 |
24 Feb 2020 | $0.3288 | 0.00% | Interim | 12 Mar 2020 |
16 Aug 2019 | $0.3833 | 0.00% | Final | 05 Sep 2019 |
22 Feb 2019 | $0.2905 | 0.00% | Interim | 14 Mar 2019 |
24 Aug 2018 | $0.3414 | 0.00% | Final | 13 Sep 2018 |
16 Feb 2018 | $0.2588 | 44.13% | Interim | 08 Mar 2018 |
18 Aug 2017 | $0.2998 | 0.00% | Final | 08 Sep 2017 |
17 Feb 2017 | $0.2638 | 0.00% | Interim | 10 Mar 2017 |
19 Aug 2016 | $0.3097 | 0.00% | Final | 08 Sep 2016 |
11 Feb 2016 | $0.2795 | 0.00% | Interim | 10 Mar 2016 |
13 Aug 2015 | $0.3119 | 0.00% | Final | 10 Sep 2015 |
12 Feb 2015 | $0.2567 | 0.00% | Interim | 11 Mar 2015 |
26 Feb 2014 | $0.1828 | 0.00% | Interim | 25 Mar 2014 |
16 Feb 2012 | $0.1050 | 0.00% | Interim | 14 Mar 2012 |
17 Feb 2011 | $0.0980 | 0.00% | Interim | 16 Mar 2011 |
31 Aug 2010 | $0.1225 | 0.00% | Final | 29 Sep 2010 |
02 Mar 2006 | $0.0630 | 0.00% | Interim | 07 Apr 2006 |
26 Sep 2005 | $0.0700 | 0.00% | Final | 18 Oct 2005 |
ANN ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Ansell Ltd
Ansell Ltd (ASX: ANN) is a leading global supplier of protective gloves and bodywear for use in healthcare and industrial settings.
The company holds a large number of patents and the majority of sales come from its key branded product ranges. It earns the bulk of its revenue and profit from the healthcare segment and the remainder from its industrial business.
The Australian company has an international manufacturing and distribution footprint and supplies its products via key partners as well as directly across more than 120 countries.
Ansell earns the bulk of its revenue from its North American market segment followed by Europe, the Middle East, and Africa. The Asia-Pacific accounts for a relatively small portion of the company's business.
ANN Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
09 Aug 2023 | $24.24 | $0.08 | 0.33% | 372,256 | $23.95 | $24.32 | $23.95 |
08 Aug 2023 | $24.16 | $0.19 | 0.79% | 220,494 | $23.93 | $24.22 | $23.93 |
07 Aug 2023 | $23.97 | $0.10 | 0.42% | 164,681 | $23.90 | $24.17 | $23.90 |
04 Aug 2023 | $23.87 | $-0.15 | -0.62% | 293,056 | $23.71 | $23.98 | $23.65 |
03 Aug 2023 | $24.02 | $0.08 | 0.33% | 287,773 | $23.94 | $24.07 | $23.80 |
02 Aug 2023 | $23.94 | $-0.41 | -1.68% | 201,125 | $24.04 | $24.25 | $23.93 |
01 Aug 2023 | $24.35 | $0.21 | 0.87% | 205,605 | $24.15 | $24.41 | $24.15 |
31 Jul 2023 | $24.14 | $-0.02 | -0.08% | 197,939 | $24.05 | $24.22 | $24.01 |
28 Jul 2023 | $24.16 | $0.25 | 1.05% | 475,809 | $23.80 | $24.20 | $23.65 |
27 Jul 2023 | $23.91 | $0.36 | 1.53% | 476,680 | $23.49 | $23.91 | $23.49 |
26 Jul 2023 | $23.55 | $-0.09 | -0.38% | 219,689 | $23.58 | $23.64 | $23.35 |
25 Jul 2023 | $23.64 | $0.05 | 0.21% | 274,483 | $23.70 | $23.83 | $23.47 |
24 Jul 2023 | $23.59 | $-0.20 | -0.84% | 404,734 | $23.82 | $24.00 | $23.45 |
21 Jul 2023 | $23.79 | $0.17 | 0.72% | 891,231 | $23.64 | $24.05 | $23.45 |
20 Jul 2023 | $23.62 | $0.34 | 1.46% | 921,069 | $23.40 | $24.12 | $23.38 |
19 Jul 2023 | $23.28 | $-0.60 | -2.51% | 1,278,638 | $23.06 | $23.53 | $23.00 |
18 Jul 2023 | $23.88 | $-3.89 | -14.01% | 2,637,724 | $24.74 | $24.74 | $23.32 |
17 Jul 2023 | $27.77 | $0.21 | 0.76% | 150,158 | $27.50 | $27.91 | $27.46 |
14 Jul 2023 | $27.56 | $-0.03 | -0.11% | 239,479 | $27.64 | $27.75 | $27.54 |
13 Jul 2023 | $27.59 | $0.42 | 1.55% | 404,093 | $27.38 | $27.78 | $27.30 |
12 Jul 2023 | $27.17 | $-0.09 | -0.33% | 188,495 | $27.35 | $27.42 | $27.13 |
11 Jul 2023 | $27.26 | $0.89 | 3.38% | 279,383 | $26.90 | $27.30 | $26.66 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
31 May 2023 | John Bevan | Buy | 149 | $3,990 |
Participation in share purchase plan.
|
31 May 2023 | Christina Stercken | Buy | 227 | $6,079 |
Participation in share purchase plan.
|
31 May 2023 | Christine Yan | Buy | 246 | $6,587 |
Participation in share purchase plan.
|
02 May 2023 | Christina Stercken | Buy | 441 | $11,950 |
Participation in share purchase plan.
|
02 May 2023 | John Bevan | Buy | 292 | $7,912 |
Participation in share purchase plan.
|
02 May 2023 | Christine Yan | Buy | 480 | $13,007 |
Participation in share purchase plan.
|
28 Feb 2023 | Christine Yan | Buy | 228 | $6,210 |
Participation in share purchase plan.
|
28 Feb 2023 | John Bevan | Buy | 138 | $3,758 |
Participation in share purchase plan.
|
28 Feb 2023 | Christina Stercken | Buy | 210 | $5,720 |
Participation in share purchase plan.
|
23 Feb 2023 | Debra (Debbie) Goodin | Buy | 486 | $12,959 |
On-market trade.
|
16 Feb 2023 | John Bevan | Buy | 150 | $3,943 |
Participation in share purchase plan.
|
16 Feb 2023 | Christina Stercken | Buy | 227 | $5,967 |
Participation in share purchase plan.
|
16 Feb 2023 | Christine Yan | Buy | 248 | $6,519 |
Participation in share purchase plan.
|
30 Dec 2022 | Christine Yan | Buy | 226 | $6,419 |
Participation in share purchase plan.
|
30 Dec 2022 | Christina Stercken | Buy | 209 | $5,936 |
Participation in share purchase plan.
|
30 Dec 2022 | John Bevan | Buy | 138 | $3,919 |
Participation in share purchase plan.
|
28 Dec 2022 | Neil Salmon | Issued | 58 | $1,654,584 |
Issue of securities. 125,699 performance share rights
|
30 Nov 2022 | John Bevan | Buy | 144 | $4,176 |
Participation in share purchase plan.
|
30 Nov 2022 | Christina Stercken | Buy | 219 | $6,351 |
Participation in share purchase plan.
|
30 Nov 2022 | Christine Yan | Buy | 239 | $6,931 |
Participation in share purchase plan.
|
31 Oct 2022 | Christine Yan | Buy | 240 | $6,715 |
Participation in share purchase plan.
|
31 Oct 2022 | Christina Stercken | Buy | 221 | $6,183 |
Participation in share purchase plan.
|
31 Oct 2022 | John Bevan | Buy | 146 | $4,085 |
Participation in share purchase plan.
|
30 Sep 2022 | John Bevan | Buy | 156 | $3,912 |
Participation in share purchase plan.
|
30 Sep 2022 | Christina Stercken | Buy | 236 | $5,918 |
Participation in share purchase plan.
|
30 Sep 2022 | Christine Yan | Buy | 257 | $6,445 |
Participation in share purchase plan.
|
08 Sep 2022 | Nigel Garrard | Buy | 850 | $22,142 |
On-market trade.
|
31 Aug 2022 | John Bevan | Buy | 146 | $3,838 |
Participation in share purchase plan.
|
31 Aug 2022 | Christina Stercken | Buy | 222 | $5,836 |
Participation in share purchase plan.
|
31 Aug 2022 | Christine Yan | Buy | 241 | $6,335 |
Participation in share purchase plan.
|
29 Aug 2022 | Morten Falkenberg | Buy | 4 | $129,937 |
On-market trade.
|
26 Aug 2022 | Christine Yan | Buy | 235 | $6,402 |
Participation in share purchase plan.
|
26 Aug 2022 | Christina Stercken | Buy | 216 | $5,885 |
Participation in share purchase plan.
|
26 Aug 2022 | John Bevan | Buy | 143 | $3,896 |
Participation in share purchase plan.
|
25 Aug 2022 | Neil Salmon | Exercise | 39 | $1,075,858 |
Conversion of securities. 66,817 performance share rights
As per announcement on 07-09-2022 |
25 Aug 2022 | Neil Salmon | Issued | 39 | $1,075,858 |
Conversion of securities.
|
25 Aug 2022 | Neil Salmon | Sell | 16 | $454,467 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Nigel David Garrard | Non-Executive Director | Mar 2020 |
Mr Garrard is an experienced executive with a track record across FMCG and Industrial/ Manufacturing sectors. Mr Garrard has 20 years' experience as an ASX-listed CEO across three companies. In 2019, Mr Garrard retired as Managing Director and CEO of Orora Limited. Mr Garrard led the demerger of Orora from Amcor, and subsequent listing on the ASX in 2013.
|
Mr William G Reilly | Non-Executive Director | Oct 2017 |
Mr Reilly has over 35 years' experience as an in-house lawyer. Mr Reilly was appointed as General Counsel of Ansell Healthcare in 2000 when it was a division of Pacific Dunlop Limited, subsequently becoming General Counsel of Ansell Limited in 2002.
|
Mr John Andrew Bevan | Non-Executive DirectorNon-Executive Chairman | Aug 2012 |
Mr Bevan was formerly the Chief Executive Officer and Executive Director of Alumina Limited and brings to the Board international business experience. Prior to joining Alumina Limited, he had a long career with the BOC Group Plc, where he was a member of the Board of Directors and held senior management positions in Australia, Korea, Thailand, Singapore and the UK.
|
Ms Debra (Debbie) Lyn Goodin | Non-Executive Director | Dec 2022 |
--
|
Ms Leslie A Desjardins | Non-Executive Director | Nov 2015 |
Ms Desjardins is a former international finance executive with experience in business performance and growth. Mrs Desjardins was formerly the Chief Financial Officer of Amcor Limited. Prior to Amcor, she held executive roles at General Motors Corporation, in Canada, the US and Australia, including Chief Financial Officer GM Holden, Controller for GM North America.
|
Mrs Christina Stercken | Non-Executive Director | Oct 2017 |
Mrs Stercken was a partner at Euro Asia Consulting PartG (EAC) until the end of 2017. In this function, Mrs Stercken helped customers in machinery, automotive, chemical, healthcare and infrastructure industries in strategy, M&A and operational excellence in growth markets.
|
Ms Christine Yingli Yan | Non-Executive Director | Feb 2019 |
Ms Yan is an experienced executive, She had a career at Stanley Black & Decker. Ms Yan has held senior management positions in both the US and China, including Vice President of Sales and Marketing for North America Automotive, President of the Global Automotive Division, President of Americas for the Engineered Fastening division, President of Stanley Storage and Workspace Systems.
|
Mr Neil Salmon | Chief Executive OfficerManaging Director | Sep 2021 |
Mr Salmon had more than 20 years of professional experience, gained working across roles in a diverse group of international businesses. He spent the first 17 years of his career with Imperial Chemical Industries (ICI) primarily in finance roles based in the UK, South Africa, the USA and Singapore before serving as Chief Financial Officer of Innophos in New Jersey, USA.
|
Morten Falkenberg | Non-Executive Director | Nov 2021 |
Mr Falkenberg is a experienced and seasoned executive with 35 years of leadership experience within FMCG, Telecoms/ Technology, and consumer durable goods companies. Prior to that Mr Falkenberg held senior positions at Electrolux, Tele Denmark and Coca-Cola and has lived outside his native Denmark in the U.S., Israel, Norway and Sweden.
|
Ms Catherine Stribley | VP Corporate Governance & Social ResponsibilityCompany Secretary | Apr 2017 |
-
|
Renae Leary | Chief Commercial Officer - Americas |
-
|
|
Francois le Jeune | Chief Commercial Officer - EMEA & APAC and Guardian Administration |
-
|
|
Zubair Javeed | Chief Financial Officer |
-
|
|
Amanda Manzoni | Chief Human Resources Officer |
-
|
|
Michael Gilleece | Corporate General Counsel |
-
|
|
Deanna Johnston | Global Chief Information Officer |
-
|
|
Darryl Nazareth | President HGBU |
-
|
|
Rikard Froberg | President IGBU |
-
|
|
Augusto Accorsi | SBU Vice President & GM HGBU Exam & Single Use |
-
|
|
Angie Phillips | SBU Vice President & GM HGBU Surgical & HSS |
-
|
|
Paul Bryce | SBU Vice President & GM IGBU Chemical Solutions |
-
|
|
Sean Sweeney | SBU Vice President & GM IGBU Mechanical Solutions |
-
|
|
John Marsden | Senior Vice President = Global Operations and Global Supply Chain |
-
|
|
Catherine Stribley | VP Corporate Governance & Social ResponsibilityCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited | 32,838,929 | 25.80% |
J P Morgan Nominees Australia Pty Limited | 18,304,332 | 14.38% |
Citicorp Nominees Pty Limited | 18,200,942 | 14.30% |
National Nominees Limited | 4,514,901 | 3.55% |
BNP Paribas Noms Pty Ltd <Drp> | 3,512,957 | 2.76% |
HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> | 2,532,328 | 1.99% |
BNP Paribas Nominees Pty Ltd HUB24 Custodial Serv Ltd <Drp A/C> | 1,485,653 | 1.17% |
CPU Share Plans Pty Ltd <Psr Nor Unallocated A/C> | 1,399,288 | 1.10% |
Australian Foundation Investment Company Limited (i) | 1,078,865 | 0.85% |
Netwealth Investments Limited <Wrap Services A/C> | 637,660 | 0.50% |
HSBC Custody Nominees (Australia) Limited A/C 2 | 517,669 | 0.41% |
Australian Executor Trustees Limited <IPS IOOF Employer Super A/C> | 363,766 | 0.29% |
Netwealth Investments Limited <Super Services A/C> | 350,499 | 0.28% |
Custodial Services Limited <Beneficiaries Holding A/C> | 331,105 | 0.26% |
Australian Executor Trustees Limited <No 1 Account> | 320,262 | 0.25% |
Citicorp Nominees Pty Limited <Colonial First State Inv A/C> | 306,042 | 0.24% |
Australian Foundation Investment Company Limited (ii) | 290,000 | 0.23% |
Citicorp Nominees Pty Limited <Citibank NY ADR Dep A/C> | 288,540 | 0.23% |
BNP Paribas Nominees Pty Ltd <Pitcher Partners DRP> | 254,087 | 0.20% |
Mirrabooka Investments Limited | 235,000 | 0.18% |